DFC Announces Financing to Support COVID-19 Vaccine Manufacturing in South Africa

You are subscribed to Africa for U.S. Department of State. This information has recently been updated, and is now available. DFC Announces Financing to Support COVID-19 Vaccine Manufacturing in South Africa 06/30/2021 01:46 PM EDT Ned Price, Department Spokesperson Today, the U.S. International Development Finance Corporation (DFC) announced a joint financing package of €600 million for Aspen Pharmacare Holdings Ltd., headquartered in South Africa, to expand local vaccine manufacturing capacity.  DFC is working together with DEG (Germany), Proparco (France), and the International Finance Corporation (IFC) to provide financing support.  The package will help increase capacity to support Aspen's efforts to produce COVID-19 vaccines with Stringent Regulatory Authorization (SRA) and/or World Health Organization (WHO) Emergency Use Listing, including the Johnson & Johnson COVID-19 vaccine. The vaccines will be primarily distributed to the African Union, South African Government, and COVAX. This effort supports the Administration's goal to scale vaccine production, invest in African ingenuity and resilience, and help the global community beat this COVID-19 pandemic. Stay connected with the State Department: External links found in this content or on Department of State websites that go to other non-Department websites should not be construed as an endorsement of the views or privacy policies contained therein.    Update your subscriptions, modify your password or email address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This email was sent to ignoble.experiment@arconati.us using GovDelivery Communications Cloud on behalf of: U.S. Department of State · 2201 C Street NW · Washington, DC 20520